News
OCS
13.80
+5.42%
0.71
Weekly Report: what happened at OCS last week (0622-0626)?
Weekly Report · 1d ago
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
TipRanks · 4d ago
Weekly Report: what happened at OCS last week (0615-0619)?
Weekly Report · 06/22 10:23
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 06/15 15:05
Weekly Report: what happened at OCS last week (0608-0612)?
Weekly Report · 06/15 10:24
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
Barchart · 06/11 03:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)
TipRanks · 06/10 16:30
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 06/10 15:05
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
Barchart · 06/09 14:21
Oculis Announces First Patient Randomized In PREDICT-1 Registrational Trial Of Licaminlimab For Dry Eye Disease
Benzinga · 06/09 08:16
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
Barchart · 06/09 03:00
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
PR Newswire · 06/08 16:43
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Barchart · 06/08 13:45
Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky
PR Newswire · 06/08 13:00
Weekly Report: what happened at OCS last week (0601-0605)?
Weekly Report · 06/08 10:20
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)
TipRanks · 06/06 14:30
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
Barchart · 06/04 15:31
Oculis Holding Is Maintained at Overweight by JP Morgan
Dow Jones · 06/03 16:35
Oculis Holding Price Target Cut to $23.00/Share From $42.00 by JP Morgan
Dow Jones · 06/03 16:35
JP Morgan Maintains Overweight on Oculis Holding, Lowers Price Target to $23
Benzinga · 06/03 16:25
More
Webull provides a variety of real-time OCS stock news. You can receive the latest news about Oculis Holding through multiple platforms. This information may help you make smarter investment decisions.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.